Hpv radiation therapy
De-escalation strategies in the oncological management of HPV-positive oropharyngeal cancer.
Source: ORL. Author s : Zahu, Renata; Sturzu, Daniela; Kacso, Gabriel; Ciuleanu, Elisabeta Abstract: HPV-positive oropharyngeal cancers hpv radiation therapy registered a rising incidence in the last two decades, especially among young nonsmoking adults. Retrospective studies have shown that the prognosis of these cancers is superior to the one of HPV-negative cancers.
The combined treatment, such as radiochemotherapy or surgery followed by adjuvant radiotherapy, causes serious acute and late toxicities, like mucositis, dysphagia, xerostomia or cervical fibrosis. Given the young age group and the better prognosis of HPV-positive cancers, a series of new strategies to deintensify the treatment have been introduced, such as lower total dose of radiotherapy, omitting chemotherapy or replacing some cytotoxic agents with other less toxic agents.
The present paper presents the standard treatment for HPV-positive cancers and a review of the published or still pending studies for de-escalation. We also list some common late toxicities with an impact on the quality of life. Copyright of ORL.
However, users may print, download, or email articles for individual use.
Radiation for hpv throat cancer, Radiation for hpv throat cancer Radiation for hpv throat cancer Radiation for hpv throat cancer Cancerul de Col Uterin Hpv radiation therapy. In addition to tobacco and alcohol abuse, certain viruses have been associated with squamous cell carcinoma SCC of the head and neck, causing alterations in DNA. It has been demonstrated that the human papillomavirus HPV type 16, a subtype of the human papillomavirus, is present in the oropharyngeal carcinomas of non-smokers patients inclusive. Materials and method.
This abstract may be abridged. No warranty is given about the accuracy of the copy.
Users should refer to the original published version of the material for the full abstract. Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use.
However, remote access to EBSCO's databases from non-subscribing institutions is not hpv radiation therapy if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.